We use cookies for a better user experience. Read our Privacy Policy

I Agree

Optic Nerve Disorders Treatment Market

Optic Nerve Disorders Treatment Market (Treatment Type: Pharmacological Treatment (Prostaglandin, Beta Interferons, Beta Blockers, Alpha-adrenergic Agonist, Carbonic Anhydrase Inhibitors, Corticosteroids, Combination Drugs, and Others), and Surgery; Indication: Glaucoma, Optic Neuritis, Optic Neuropathy (Arteritic Ischemic Optic Neuropathy, Non-arteritic Ischemic Optic Neuropathy, and Congenital Optic Atrophy), and Others; and End User: Hospitals, Ambulatory Surgery Centers, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

New Treatment Options for Glaucoma through Precision Medicines and Topical Treatments in Offing

Emergence of topical treatments are creating incremental opportunities for manufacturers operating in the optic nerve disorders treatment market. For instance, Canadian manufacturers of eye health products Bausch & Lomb, announced the launch of VYZULTA® — a topical glaucoma treatment solution that gained acceptance by the Government of Canada.

Companies in the optic nerve disorders treatment market are increasing treatment options for glaucoma, since the glaucoma indication segment of the optic nerve disorders treatment market is projected for exponential growth during the forecast period. The glaucoma segment is expected to reach a value of ~US$ 12.1 Bn by the end of 2023. Hence, manufacturers are increasing efficacy in precision medication to offer treatment options for glaucoma.

To innovate in precision medicines, manufacturers in the market for optic nerve disorders treatment are increasing research to understand the aqueous humor for anterior segment and trabecular meshwork tissue.

optic nerve disorders treatment market infographic

To know the scope of our report Get a Sample on Optic Nerve Disorders Treatment Market ?

Advancements in Beta Interferons Benefit MS Patients

High prevalence of multiple sclerosis (MS) patients is one of the key drivers for the growth of optic nerve disorders treatment market. Hence, manufacturers are increasing production capabilities to develop immunosuppressive drugs that improve quality of life in patients. For instance, in September 2019, Swiss multinational healthcare company Roche revealed its proceedings on trials for OCREVUS® — an immunosuppressive drug, to understand its effects in relapsing and progressive MS.

Companies in the optic nerve disorders treatment market are increasing trials of immunosuppressive drugs with beta interferons to provide relief to MS patients. As such, the beta interferons sub-segment of the pharmacological treatment segment is estimated to reach a value of ~US$ 2.5 Bn by 2027. Hence, manufacturers in the optic nerve disorders treatment market are increasing production capabilities in beta interferons, since pharmacological treatment segment is anticipated for aggressive growth during the forecast period. Moreover, the neurofilament light chain-lowering capabilities of beta interferons are increasingly benefitting MS patients.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies Focus on Unmet Needs of NMOSD Patients in Europe

New drugs for rare neurologic eye diseases are being extensively researched for the treatment of MS and neuromyelitis optica. Striking correlation between neurologic diseases and rare eye conditions have opened the doors for innovation in the optic nerve disorders treatment market.

On the other hand, terminal complement inhibitors are under scrutiny of the European and Japanese health commissions. As such, companies are focusing to extend their product portfolios into Europe and Japan, since the two regions are projected for exponential growth during the forecast period. For instance, in June 2019, Alexion — a U.S. pharmaceutical company, announced that the European Medicines Agency and Japanese Ministry of Health, Labor and Welfare are assessing applications of SOLIRIS® for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

The optic nerve disorders treatment market in Europe is expected to reach a value of ~US$ 4.2 Bn. Thus, manufacturers in the market for optic nerve disorders treatment are focusing on meeting the needs of patients in Europe, since NMOSD is a rare disease.

Innovations in Corticosteroids Meet Post Ocular Surgery Requirements

Innovations in topical ocular corticosteroids are proving to be beneficial for patients in the management of pain and inflammation post ocular surgery. However, limitations of these corticosteroids, such as limited bioavailability and class-associated adverse events (AE) are some of the barriers that companies in the optic nerve disorders treatment market have to counter. Hence, manufacturers in the optic nerve disorders treatment market are educating healthcare providers about drug-specific variables of topical ocular corticosteroids, such as AE profile, potency, and patient-specific administration needs for better outcomes in patients.

Companies in the market for optic nerve disorders treatment are aiming at minimizing precorneal drug loss and maximizing drug delivery to the anterior tissues with the help of improved corticosteroid formulations. They are adopting various strategies to enhance ocular penetration by including mucoadhesive formulations in the development of new corticosteroids. Strategies, such as drug-particle size reduction enable faster drug dissolution, which increases bioavailability and penetration. Hence, companies in the optic nerve disorders treatment market are increasing the production capacities of loteprednol etabonate corticosteroids using retrometabolic drug design.

optic nerve disorders treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Companies in the optic nerve disorders treatment market are tapping into new opportunities to obtain new clues from drugs used in neurological disorders for treatment of vision-related diseases. For instance, in May 2019, Bionure — a Spanish biotechnology company, announced its successful investigation for its neuroprotectant BN201, which holds promising results in the treatment of MS and acute optic neuritis.

However, poor bioavailability of drugs for efficacious ocular drug delivery poses as a challenge for manufacturers. Hence, companies should innovate in ocular therapeutics to improve biopharmaceutical properties of drugs. They should focus on expanding product portfolio of drugs that treat optic neuritis, since this indication is projected to gain significant prominence during the forecast period.

Optic Nerve Disorders Treatment Market: Overview

  • Increase in prevalence of eye disorders is the major driver of the global optic nerve disorders treatment market
  • Optic nerve disorders treatment covers treatment options for optic nerve disorders, which include pharmacological treatment consisting of medications and surgery
  • Glaucoma is one of the major indications resulting from optic nerve damage and is a common ophthalmologic condition
  • Optic nerve disorders are caused due to the damage to optic nerves, which can result in vision loss and eventually complete blindness
  • These disorders include glaucoma, optic neuritis, optic neuropathy, idiopathic intracranial hypertension, optic nerve drusen, and other disorders associated with the optic nerves
  • According to the American Academy of Ophthalmology, in 2011, 2.71 million people in the U.S. had primary open-angle glaucoma (POAG)
  • Growing aging population prone to ophthalmological conditions, and high adoption rate and usage of digital devices are some of the concerning factors leading to eye related disorders

Optic Nerve Disorders Treatment Market: Segmentation

  • Based on treatment type, the optic nerve disorders treatment market has been bifurcated into pharmacological treatment and surgery
  • Pharmacological treatment has been further classified into prostaglandins, beta interferons, beta blockers, alpha-adrenergic agonist, carbonic anhydrase inhibitors, corticosteroids, combination drugs, and others
  • In terms of indication, the optic nerve disorders treatment market has been segmented into glaucoma, optic neuritis, optic neuropathy, and others
  • Optic neuropathy segment has been further sub-segmented into arteritic ischemic optic neuropathy, non-arteritic ischemic optic neuropathy, and congenital optic atrophy
  • In terms of end user, the optic nerve disorders treatment market has been segmented into hospitals, ambulatory surgery centers, clinics, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
  • The report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment, along with the market size estimations for the period 2019 to 2027.

Optic Nerve Disorders Treatment Market: Regional Overview

  • In terms of region, the optic nerve disorders treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • The current and future market size, in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful market insights, which will help new companies planning to enter the market and existing companies to increase market share, and help in the decision-making process

Major Players in Global Market

  • The report concludes with the company profiles section that includes key information about the major players in the optic nerve disorders treatment market
  • Key players analyzed in this report are
    • Santen Pharmaceutical Co., Ltd.,
    • Allergan plc.
    • Novartis AG
    • Pfizer, Inc.
    • Bausch Health Companies, Inc.
    • Aerie Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bionure Farma, S.L.
    • Mallinckrodt Pharmaceuticals
  •  Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Optic Nerve Disorders Treatment Market – Segmentation

TMR’s study on the optic nerve disorders treatment market includes information divided into four sections ? treatment type, indication, end user, and region. Changing industry trends and other crucial market dynamics associated with these sections of the optic nerve disorders treatment market have been discussed in detail.

Treatment Type

  • Pharmacological Treatment
    • Prostaglandins
    • Beta Interferons
    • Beta Blockers
    • Alpha-adrenergic Agonists
    • Carbonic Anhydrase Inhibitors
    • Corticosteroids
    • Combination Drugs
    • Others
  • Surgery

Indication

  • Glaucoma
  • Optic Neuritis
  • Optic Neuropathy
    • Arteritic Ischemic Optic Neuropathy
    • Non-arteritic Ischemic Optic Neuropathy
  • Congenital Optic Atrophy
  • Others

End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Clinics
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of optic nerve disorders treatment market?

Optic nerve disorders treatment market to reach a valuation of ~US$ 19.5 Bn by 2027

What is the anticipated CAGR of the optic nerve disorders treatment market in the forecast period?

Optic nerve disorders treatment market is expected to expand at a CAGR of ~4% during the forecast period from 2019 to 2027

What are the key driving factors for the growth of the optic nerve disorders treatment market?

Optic nerve disorders treatment market is driven by increase in prevalence of eye disorders

Which region is expected to project the highest market share in the global optic nerve disorders treatment market?

North America accounted for a major share of the optic nerve disorders treatment market, and is projected to remain dominant during the forecast period

Who are the key players in the global optic nerve disorders treatment market?

Key players in the global optic nerve disorders treatment market include Santen Pharmaceutical Co., Ltd., Allergan plc. Novartis AG, Pfizer, Inc., Bausch Health Companies

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Optic Nerve Disorders Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Key Vendor and Distributor Analysis

    5.3. Technological Advancements

    5.4. Prevalence & Incidence of Optic Nerve Disorders

    5.5. Regulatory Scenario Assessment

6. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Treatment Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Treatment Type, 2017–2027

        6.3.1. Pharmacological Treatment

            6.3.1.1. Prostaglandins

            6.3.1.2. Beta Interferons

            6.3.1.3. Beta Blockers

            6.3.1.4. Alpha-adrenergic Agonist

            6.3.1.5. Carbonic Anhydrase Inhibitors

            6.3.1.6. Corticosteroids

            6.3.1.7. Combination Drugs

            6.3.1.8. Others

        6.3.2. Surgery

    6.4. Market Attractiveness By Treatment Type, 2019-2027

7. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Indication 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By Indication, 2017–2027

        7.3.1. Glaucoma

        7.3.2. Optic Neuritis

        7.3.3. Optic Neuropathy

            7.3.3.1. Arteritic ischemic optic neuropathy

            7.3.3.2. Non-arteritic ischemic optic neuropathy

            7.3.3.3. Congenital Optic Atrophy

        7.3.4. Others

    7.4. Market Attractiveness By Indication, 2019-2027

8. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By End-user 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast By End-user, 2017–2027

        8.3.1. Hospitals

        8.3.2. Ambulatory Surgery Centers

        8.3.3. Clinics

        8.3.4. Others

    8.4. Market Attractiveness By End-user, 2019-2027

9. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Region

    9.1. Key Findings

    9.2. Market Value Forecast By Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness By Country/Region, 2019-2027

10. North America Optic Nerve Disorders Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast By Treatment Type, 2017–2027

        10.2.1. Pharmacological Treatment

            10.2.1.1. Prostaglandins

            10.2.1.2. Beta Interferons

            10.2.1.3. Beta Blockers

            10.2.1.4. Alpha-adrenergic Agonist

            10.2.1.5. Carbonic Anhydrase Inhibitors

            10.2.1.6. Corticosteroids

            10.2.1.7. Combination Drugs

            10.2.1.8. Others

        10.2.2. Surgery

    10.3. Market Value Forecast By Indication, 2017–2027

        10.3.1. Glaucoma

        10.3.2. Optic Neuritis

        10.3.3. Optic Neuropathy

            10.3.3.1. Arteritic ischemic optic neuropathy

            10.3.3.2. Non-arteritic ischemic optic neuropathy

            10.3.3.3. Congenital Optic Atrophy

        10.3.4. Others

    10.4. Market Value Forecast By End-user, 2017–2027

        10.4.1. Hospitals

        10.4.2. Ambulatory Surgery Centers

        10.4.3. Clinics

        10.4.4. Others

    10.5. Market Value Forecast By Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Treatment Type 

        10.6.2. By Indication 

        10.6.3. By End-user 

        10.6.4. By Country

11. Europe Optic Nerve Disorders Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast by Treatment Type, 2017–2027

        11.2.1. Pharmacological Treatment

            11.2.1.1. Prostaglandins

            11.2.1.2. Beta Interferons

            11.2.1.3. Beta Blockers

            11.2.1.4. Alpha-adrenergic Agonist

            11.2.1.5. Carbonic Anhydrase Inhibitors

            11.2.1.6. Corticosteroids

            11.2.1.7. Combination Drugs

            11.2.1.8. Others

        11.2.2. Surgery

    11.3. Market Value Forecast by Indication, 2017–2027

        11.3.1. Glaucoma

        11.3.2. Optic Neuritis

        11.3.3. Optic Neuropathy

            11.3.3.1. Arteritic ischemic optic neuropathy

            11.3.3.2. Non-arteritic ischemic optic neuropathy

            11.3.3.3. Congenital Optic Atrophy

        11.3.4. Others

    11.4. Market Value Forecast by End-user, 2017–2027

        11.4.1. Hospitals

        11.4.2. Ambulatory Surgery Centers

        11.4.3. Clinics

        11.4.4. Others

    11.5. Market Value Forecast by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Treatment Type 

        11.6.2. By Indication 

        11.6.3. By End-user 

        11.6.4. By Country

12. Asia Pacific Optic Nerve Disorders Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast by Treatment Type, 2017–2027

        12.2.1. Pharmacological Treatment

            12.2.1.1. Prostaglandins

            12.2.1.2. Beta Interferons

            12.2.1.3. Beta Blockers

            12.2.1.4. Alpha-adrenergic Agonist

            12.2.1.5. Carbonic Anhydrase Inhibitors

            12.2.1.6. Corticosteroids

            12.2.1.7. Combination Drugs

            12.2.1.8. Others

        12.2.2. Surgery

    12.3. Market Value Forecast by Indication, 2017–2027

        12.3.1. Glaucoma

        12.3.2. Optic Neuritis

        12.3.3. Optic Neuropathy

            12.3.3.1. Arteritic ischemic optic neuropathy

            12.3.3.2. Non-arteritic ischemic optic neuropathy

            12.3.3.3. Congenital Optic Atrophy

        12.3.4. Others

    12.4. Market Value Forecast by End-user, 2017–2027

        12.4.1. Hospitals

        12.4.2. Ambulatory Surgery Centers

        12.4.3. Clinics

        12.4.4. Others

    12.5. Market Value Forecast by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Treatment Type 

        12.6.2. By Indication 

        12.6.3. By End-user 

        12.6.4. By Country

13. Latin America Optic Nerve Disorders Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast by Treatment Type, 2017–2027

        13.2.1. Pharmacological Treatment

            13.2.1.1. Prostaglandins

            13.2.1.2. Beta Interferons

            13.2.1.3. Beta Blockers

            13.2.1.4. Alpha-adrenergic Agonist

            13.2.1.5. Carbonic Anhydrase Inhibitors

            13.2.1.6. Corticosteroids

            13.2.1.7. Combination Drugs

            13.2.1.8. Others

        13.2.2. Surgery

    13.3. Market Value Forecast by Indication, 2017–2027

        13.3.1. Glaucoma

        13.3.2. Optic Neuritis

        13.3.3. Optic Neuropathy

            13.3.3.1. Arteritic ischemic optic neuropathy

            13.3.3.2. Non-arteritic ischemic optic neuropathy

            13.3.3.3. Congenital Optic Atrophy

        13.3.4. Others

    13.4. Market Value Forecast by End-user, 2017–2027

        13.4.1. Hospitals

        13.4.2. Ambulatory Surgery Centers

        13.4.3. Clinics

        13.4.4. Others

    13.5. Market Value Forecast By Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Treatment Type 

        13.6.2. By Indication 

        13.6.3. By End-user 

        13.6.4. By Country

14. Middle East & Africa Optic Nerve Disorders Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast by Treatment Type, 2017–2027

        14.2.1. Pharmacological Treatment

            14.2.1.1. Prostaglandins

            14.2.1.2. Beta Interferons

            14.2.1.3. Beta Blockers

            14.2.1.4. Alpha-adrenergic Agonist

            14.2.1.5. Carbonic Anhydrase Inhibitors

            14.2.1.6. Corticosteroids

            14.2.1.7. Combination Drugs

            14.2.1.8. Others

        14.2.2. Surgery

    14.3. Market Value Forecast by Indication, 2017–2027

        14.3.1. Glaucoma

        14.3.2. Optic Neuritis

        14.3.3. Optic Neuropathy

            14.3.3.1. Arteritic ischemic optic neuropathy

            14.3.3.2. Non-arteritic ischemic optic neuropathy

            14.3.3.3. Congenital Optic Atrophy

        14.3.4. Others

    14.4. Market Value Forecast by End-user, 2017–2027

        14.4.1. Hospitals

        14.4.2. Ambulatory Surgery Centers

        14.4.3. Clinics

        14.4.4. Others

    14.5. Market Value Forecast by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Treatment Type 

        14.6.2. By Indication 

        14.6.3. By End-user 

        14.6.4. By Country

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Position/Ranking Analysis, By Tier and Size of the Company (2018)

    15.3. Company Profiles

        15.3.1. Santen Pharmaceutical Co., Ltd.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Allergan plc.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Novartis AG

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Pfizer, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Bausch Health Companies, Inc.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Aerie Pharmaceuticals, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Teva Pharmaceutical Industries Ltd.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Bionure Farma, S.L.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Mallinckrodt Pharmaceuticals

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

List of Tables

Table 01: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

Table 02: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

Table 03: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

Table 04: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

Table 05: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

Table 06: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027 

Table 07: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027 

Table 08: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

Table 09: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

Table 10: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

Table 11: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

Table 12: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

Table 13: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 14: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

Table 15: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

Table 16: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

Table 17: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

Table 18: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

Table 19: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 20: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

Table 21: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

Table 22: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

Table 23: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

Table 24: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

Table 25: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 26: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

Table 27: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

Table 28: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

Table 29: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

Table 30: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

Table 31: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 32: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

Table 33: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

Table 34: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

Table 35: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

Table 36: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Figures

Figure 01: Global Optic Nerve Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Optic Nerve Disorders Treatment Market Value Share, by Treatment Type (2018)

Figure 04: Global Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment (2018)

Figure 05: Global Optic Nerve Disorders Treatment Market Value Share, by Indication (2018)

Figure 06: Global Optic Nerve Disorders Treatment Market Value Share, by End-user (2018)

Figure 07: Global Optic Nerve Disorders Treatment Market Value Share, by Region (2018)

Figure 08: Regulatory Approval Process - The U.S.  

Figure 09: Regulatory Approval Process - Europe 

Figure 10: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 11: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Pharmacological Treatment, 2018 and 2027

Figure 12: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacological Treatment, 2017–2027

Figure 13: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgery, 2017–2027

Figure 14: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prostaglandins, 2017-2027

Figure 15: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Interferons, 2017-2027

Figure 16: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2017-2027

Figure 17: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Alpha-adrenergic agonist, 2017-2027

Figure 18: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Carbonic Anhydrase Inhibitors, 2017-2027

Figure 19: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroidss, 2017-2027

Figure 20: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Combination Drugs, 2017-2027

Figure 21: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

Figure 22: Global Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 23: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 24: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glaucoma, 2017-2027

Figure 25: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Optic Neuritis, 2017-2027

Figure 26: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Optic Neuropathy, 2017-2027

Figure 27: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

Figure 28: Global Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027

Figure 29: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 30: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027

Figure 31: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ambulatory Surgery Centers, 2017–2027

Figure 32: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2017–2027

Figure 33: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Academic & Research Institutes, 2017–2027

Figure 34: Global Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027

Figure 35: Global Optic Nerve Disorders Treatment Market Value Share, by Region, 2018 and 2027

Figure 36: Global Optic Nerve Disorders Treatment Market Attractiveness, by Region, 2019–2027

Figure 37: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 38: North America Optic Nerve Disorders Treatment Market Value Share, by Country, 2018 and 2027

Figure 39: North America Optic Nerve Disorders Treatment Market Attractiveness, by Country, 2019–2027

Figure 40: North America Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 41: North America Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

Figure 42: North America Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027

Figure 43: North America Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

Figure 44: North America Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

Figure 45: North America Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

Figure 46: North America Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

Figure 47: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 48: Europe Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

Figure 49: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027 

Figure 50: Europe Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 51: Europe Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

Figure 52: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027

Figure 53: Europe Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

Figure 54: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

Figure 55: Europe Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

Figure 56: Europe Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

Figure 57: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 58: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

Figure 59: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027 

Figure 60: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 61: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

Figure 62: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027

Figure 63: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

Figure 64: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

Figure 65: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

Figure 66: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

Figure 67: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 68: Latin America Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

Figure 69: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 70: Latin America Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 71: Latin America Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

Figure 72: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 73: Latin America Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

Figure 74: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

Figure 75: Latin America Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

Figure 76: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

Figure 77: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 78: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

Figure 79: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 80: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 81: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

Figure 82: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 83: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

Figure 84: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

Figure 85: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

Figure 86: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

Figure 87: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved